Back to Results
First PageMeta Content
Atypical antipsychotics / Lactams / Organofluorides / Piperidines / Schizophrenia / Paliperidone / Antipsychotic / Risperidone / Clinical trial / Psychiatry / Chemistry / Medicine


21999S024 Paliperidone Clinical PREA
Add to Reading List

Open Document

File Size: 2,89 MB

Share Result on Facebook

City

Helsinki / Reference / /

Company

Johnson & Johnson / Ortho McNeil-Janssen Pharmaceuticals Inc. / Johnson & Johnson Pharmaceutical Research & Development L.L.C. / The AEs / ITT / Janssen Pharmaceuticals / Inc. / /

Country

Russia / United States / Canada / India / /

Event

FDA Phase / /

Facility

Laboratory Findings / /

IndustryTerm

treatment of schizoaffective disorder / foreign site / /

MedicalCondition

Treatment-Emergent Orthostatic Hypotension / Schizophrenia / dementia / sudden cardiac death / seizures / schizopheniform disorder / stroke / schizoaffective disorder / orthostatic hypotension / hyperglycemia/ diabetes mellitus / neuroleptic malignant syndrome / tardive dyskinesia / agranulocytosis / adolescent schizophrenia / hyperprolactinemia / /

Organization

Division of Scientific Investigation / FDA / European Union / Advisory Committee / /

Person

HOMA IR / /

Product

olanzapine / ER tablet / Invega / ER Tablets / Therapeutic Class Atypical Antipsychotic Applicant Johnson & Johnson Formulations Oral Extended-Release Tablets / Risperdal / Paliperidone ER / Seroquel / risperidone / Abilify / Paliperidone ER tablet / Zyprexa / S014 / S-013 / ER / PSZ-3001 / US / /

PublishedMedium

Baseline / /

Technology

Adam / /

SocialTag